Price Action Alert: Is Tandem Diabetes Care Inc a Buy? The Stock Rises Again

Price Action Alert: Is Tandem Diabetes Care Inc a Buy? The Stock Rises Again

The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) is a huge mover today! The stock increased 6.38% or $0.15 on November 23, hitting $2.5. About 436,214 shares traded hands. Tandem Diabetes Care Inc (NASDAQ:TNDM) has declined 75.07% since April 22, 2016 and is downtrending. It has underperformed by 80.48% the S&P500.
The move comes after 7 months positive chart setup for the $65.46 million company. It was reported on Nov, 24 by Barchart.com. We have $2.73 PT which if reached, will make NASDAQ:TNDM worth $5.89 million more.

Analysts await Tandem Diabetes Care Inc (NASDAQ:TNDM) to report earnings on February, 22. They expect $-0.62 EPS, down 55.00% or $0.22 from last year’s $-0.4 per share. After $-0.97 actual EPS reported by Tandem Diabetes Care Inc for the previous quarter, Wall Street now forecasts -36.08% EPS growth.

Tandem Diabetes Care Inc (NASDAQ:TNDM) Ratings Coverage

Out of 9 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 3 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 33% are positive. Tandem Diabetes Care has been the topic of 17 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Deutsche Bank maintained the shares of TNDM in a report on Monday, August 10 with “Buy” rating. The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) earned “Buy” rating by Feltl & Co on Wednesday, November 2. The stock has “Hold” rating given by Stifel Nicolaus on Wednesday, November 2. As per Thursday, August 20, the company rating was downgraded by Zacks. The stock has “Hold” rating given by Zacks on Friday, September 4. The firm earned “Neutral” rating on Thursday, January 14 by Bank of America. The stock has “Buy” rating given by Deutsche Bank on Wednesday, November 2. As per Wednesday, August 5, the company rating was upgraded by Zacks. The rating was downgraded by Robert W. Baird to “Neutral” on Wednesday, November 2. The company was downgraded on Thursday, November 3 by Piper Jaffray.

According to Zacks Investment Research, “Tandem Diabetes Care, Inc. is a medical device company. The Company designs, develops, and commercializes products for people with insulin-dependent diabetes. Its products include t:slim Insulin Delivery System. Tandem Diabetes Care, Inc. is headquartered in San Diego, California.”

Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.30, from 1.02 in 2016Q1. The ratio increased, as 18 funds sold all Tandem Diabetes Care Inc shares owned while 24 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 17.85 million shares or 6.33% less from 19.06 million shares in 2016Q1.
Senzar Asset Mgmt Ltd Com owns 615,311 shares or 0% of their US portfolio. Envestnet Asset Mngmt holds 0% or 1,649 shares in its portfolio. Rock Springs Cap Mngmt Limited Partnership, a Maryland-based fund reported 595,000 shares. The New York-based Art Advsrs Lc has invested 0.01% in Tandem Diabetes Care Inc (NASDAQ:TNDM). Bnp Paribas Arbitrage reported 720 shares or 0% of all its holdings. Manufacturers Life The holds 0% or 4,864 shares in its portfolio. Eventide Asset Mgmt Limited Liability Co, a Massachusetts-based fund reported 275,000 shares. Rhumbline Advisers has invested 0% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM). The New Jersey-based Blackrock Mngmt Ltd Liability has invested 0% in Tandem Diabetes Care Inc (NASDAQ:TNDM). American Intll Inc has invested 0% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM). Dafna Ltd Llc holds 1.87% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM) for 312,756 shares. National Bank Of New York Mellon accumulated 214,673 shares or 0% of the stock. Morgan Stanley has invested 0% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM). Iguana Healthcare Mgmt Limited reported 175,000 shares or 0.54% of all its holdings. Ladenburg Thalmann Fincl Services holds 0% or 300 shares in its portfolio.

More news for Tandem Diabetes Care Inc (NASDAQ:TNDM) were recently published by: Businesswire.com, which released: “Tandem Diabetes Care Reports Third Quarter 2016 Financial Results” on November 01, 2016. Businesswire.com‘s article titled: “NIH-funded International Diabetes Closed Loop (IDCL) Trial to Combine …” and published on November 10, 2016 is yet another important article.

TNDM Company Profile

Tandem Diabetes Care, Inc., incorporated on January 7, 2008, is a medical device company. The Firm is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Firm makes and sells over three insulin pump products in the United States that are designed to address insulin-dependent diabetes market, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). The Company’s technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism. The Firm also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud data management application that provides display therapy management data from the pump and supported blood glucose meters.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment